Novocure Reports Third Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
JMP Securities Starts NovoCure Ltd. (NVCR) at Market Outperform
October 27, 2015 8:18 AM EDTJMP Securities initiated coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Market Outperform rating and a price target of $43.00.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $20.58 yesterday.
... MoreWedbush Starts NovoCure Ltd. (NVCR) at Outperform
October 27, 2015 7:28 AM EDTWedbush initiates coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Outperform rating and a price target of $30.00.
Analyst Tao Levy commented, " NovoCure is a rapidly emerging, commercial stage company whose flagship Tumor Treating Fields (TTFields) technology reverses tumor growth by disrupting cell... More
Novocure (NVCR) Reports Q3 Loss of $2.09/Share
October 26, 2015 4:14 PM EDTNovocure (NASDAQ: NVCR) reported Q3 EPS of ($2.09), versus ($1.45) reported last year. Revenue for the quarter came in at $8.95 million, versus $4.37 million reported last year.
Third Quarter 2015 Operating Statistics
354 prescriptions were received in the quarter, an... More